Drug Information

Drug General Information
Drug ID
D09QZS
Former ID
DNCL002598
Drug Name
Olaratumab
Synonyms
LY3012207
Drug Type
Monoclonal antibody
Indication Soft tissue sarcoma [ICD9: 171; ICD10:C00-D49] Approved [889440]
Non-small cell lung cancer; Ovarian cancer [ICD9: 183; ICD10:C33-C34, C56] Phase 1 [525103]
Company
Eli Lilly
CAS Number
CAS 1024603-93-7
Target and Pathway
Target(s) Alpha platelet-derived growth factor receptor Target Info Modulator [532640]
KEGG Pathway MAPK signaling pathway
Ras signaling pathway
Rap1 signaling pathway
Calcium signaling pathway
Cytokine-cytokine receptor interaction
Endocytosis
PI3K-Akt signaling pathway
Focal adhesion
Gap junction
Regulation of actin cytoskeleton
HTLV-I infection
Pathways in cancer
MicroRNAs in cancer
Glioma
Prostate cancer
Melanoma
Central carbon metabolism in cancer
Choline metabolism in cancer
NetPath Pathway TGF_beta_Receptor Signaling Pathway
PANTHER Pathway Angiogenesis
PDGF signaling pathway
Pathway Interaction Database ATF-2 transcription factor network
PDGFR-alpha signaling pathway
PDGF receptor signaling network
Reactome PIP3 activates AKT signaling
Constitutive Signaling by Aberrant PI3K in Cancer
RAF/MAP kinase cascade
WikiPathways Regulation of Actin Cytoskeleton
Osteoblast Signaling
Focal Adhesion
Hair Follicle Development: Organogenesis (Part 2 of 3)
PIP3 activates AKT signaling
Cardiac Progenitor Differentiation
Integrated Pancreatic Cancer Pathway
Allograft Rejection
Signaling Pathways in Glioblastoma
Signaling by PDGF
Angiogenesis
References
Ref 525103ClinicalTrials.gov (NCT02377752) A Study of Olaratumab in Japanese Participants With Advanced Cancer. U.S. National Institutes of Health.
Ref 8894402016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. doi: 10.1038/nrd.2017.14.
Ref 532640A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.